FRI0171 Evaluating Treatment Efficacy in Rheumatoid Arthritis: Interrelation Disease Activity – Functional Status – Utility

BackgroundRheumatoid Arthritis (RA) treatment targets remission or low disease activity. Patient Registries offer real-world data about effectiveness on long term. Comparing different tools for assessing effectiveness (disease activity, functional status and utility) could provide a more comprehensive approach on the term “achieve and maintain” the therapeutic goal, as a measure of efficacy.ObjectivesTo evaluate interrelations of disease activity – functional status – utility in a group of RA patients, treated with tumor necrosis factor alpha (TNF) antagonists and anti CD20 molecule, as well as any factor that could influence it.MethodsCross-sectional study carried out over a cohort of RA patients in Romania. Data was gathered from the Romanian Registry of Rheumatic Diseases and included only RA patients treated with biologics, for who were available all three variables under study: EQ5D (for utility), HAQ score (for functional status), and DAS28 and SDAI (for disease activity). The interrelations of the efficacy parameters were analyzed using correlation tests, T test, ANOVA.ResultsThe study cohort included 777 RA patients, mean age 58.72 (±12.37) yrs, 84.4% women, mean RA duration 14.08 (±8.33) yrs, 77.1% retired, treated with etanercept (30.6%), adalimumab (22.7%), infliximab (original 6.3%, biosimilars 0.7%), rituximab (26.3%) with a mean treatment duration 174.90 (±143.40) weeks; 27.3% used steroids (20.2% with